<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 68 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page67.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=68">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 68 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 68</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=68"><img src="../thumb/68.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Central Nervous System - 1.6                                                    2020-04 / 37
       200 mg. If in wk.1 300 mg then wk.2: 225 mg & wk.3: 150 mg. If in   Lennox-Gastaut Syndr: Dos.guidelines as above for adults &   MYLAN OXCARBAZEPINE, (Mylan) Xixia [P/S]
       wk.1 200 mg then wk.2: 150 mg & wk.3: 100 mg. Follow.withdr.of   childr.aged 2-12 yrs.  Oxcarbazepine
       other psychotrop./ AED drugs with no known interacts. with   Contraindications: Monother.in childr.und.12 yrs. not recomm.,   Indications: Part.seiz.with/without second. generalis. seiz., general.
       lamotrigine (e.g. Li/bupropion): Maint. target.dos.achiev.in dos.  safety in pregn.& lactat.not est., hepat./ren.impairm., safety & effic.  tonic-clonic seiz.as monother. & in combin.with other anti-epilept.in
       escalat.throughout withdr. of other med.  in childr.und.2 yrs.& pts.over 65 yrs not est.  adults & childr 6 years and over.
       Lamotrigine dly.dos.adjustm.in Bipol. disord. follow.addit.of   Side effects: Sev.skin rash with irrevers.scarr.& assoc.death incl.tox.  (S3) TABS. 42/2.5/0355, 41/2.5/1106
       other meds: Addit.of enzyme inhibit.(eg.valproate). With curr.   epiderm.necrolys & Stevens-Johnson syndr.esp.in childr.& pts.on con-  717226-001: 300 mg, 50, R265,32
       stabilisat. dos. 200 mg/day: Wk.1 100 mg/day which is to be maint.  com. valproate, bld.dyscras., hypersens.syndr., photosens., CNS effs.,   717227-001: 600 mg, 50, R499,58
       through wk.2 & wk.3 onwards. With curr. stabilisat.dos.300 mg/day:   nystagm., trem., angioed., vis. disturbs., GI disturbs.  Dosage: Either as mono/adjunct.ther. Admin.dos. in 2 div.dos., incr.
       Wk.1 150 mg/day which is to be maint.through wk. 2 & wk.3 onwards.   Special precautions: Sev.convuls.seiz.incl. status epilept.may   depend.on clinic.respons. The dos.of other anti-epilept.to be reduc.
       With curr.stabilisat.dos. 400 mg/day: Wk.1 200 mg/day which is to be   lead.to rhabdomyolys./multiorg. dysfunct.& disseminat.intravasc.   grad.while ther.with Mylan Oxcarbazepine init. should other anti-ep-
       maint. through wk. 2 & wk.3 onwards. Addit.of enzyme induc. (eg.  coagulat., close monit.of hepat./ren., & clott.paramet., consid.   ilept.be replac. In adjunct.ther.it may be necess.to low.dos.of other
       carbamazepine)when NOT tak.valproate. With curr.stabilisat.  withdr. if combinat.of unexplain.rash/fev./flu-like sympts./drowsin.  anti-epilept.&/or incr. Mylan Oxcarbazepine more slow.
       dos. 200 mg/day: Wk.1 200 mg, in wk.2 300 mg & in wk.3 onwards   or worsen.of seiz.contr.dur.1st mnth.of treatm.exper., abrupt.withdr.  Adults: Monother: Init: 600 mg/day (8-10 mg/ kg/day)in 2 div.dos.
       400 mg. With curr.stabilisat.dos. 150 mg/day: Wk.1 150 mg, in wk.2   may provoke rebound seiz., grad.withdr., monit.childr.weight to maint.  May be incr.if clinic.indic.in increm.of max. 600 mg/day at interv.
       225 mg & in wk.3 onwards 300 mg. With curr. stabilisat.dos. 100 mg/  therap. dos., eval.all pts.prompt.if rash. occur., adhere to recomm.  of approx. 1 wk unt.respons.achiev. Therap.eff.achiev.betw. 600-
       day: Wk.1 100 mg, in wk.2 150 mg & in wk.3 onwards 200 mg. Ad-  dos.esp.if valproate used concom., report change in menstr.pattern   2400 mg/day. Dos.incr.up to 2400 mg/day over 48 hrs have been
       dit.of other psychotrop./ AED drugs with no known interacts.   in pts. tak. OC’s, as an inhibit.of dihydrofol.reductase exerc. caut.  giv.und.contr.hospit.condits.
       with lamotrigine (e.g. Li/bupropion): Maint.target.dos.achiev.in   with other folate antagon.  Adjunct.ther: Init: 600 mg/day (8-10 mg/kg/day) in 2 div. dos. May
       dos. escalat.(200 mg/ day) with range of 100-400 mg.  Drug interactions: Anti-epilept.agents which induc. hepat.drug   be incr.if clinic.indic.in increm.of max.of 600 mg/day at interv.of ap-
                           st
       Side effects: V.common: Skin rash gen.with.1  8 wks. with irrevers.  metabol.enzymes signific. enhanc. metabol., valproic acid incr.  prox.1 wk until. desir. respons.achiev. Therap.eff.achiev.with dos.
       scarr.& assoc.death also report. as part of hypersens.syndr., headache,   plasma conc.  betw. 600-2400 mg/day. Dly.dos.of 600-2400 mg/ kg/day have been
       dizzin., diplop., blurr.vis. Common: Irritabil., drowsin., insomn., dizzin.,   LEVETIRACETAM UNICORN, Unicorn [P/S]  effect.in studies with contr. adjunct.ther.though most pts.were unable
       trem., vertigo, parasthes., nystagm., atax., naus., GI disturbs., tiredn.,   Levetiracetam  toler. 2400 mg/day without reduct.of other anti-epilept. Dly.dos.above
       arthralg., pain, back pain. Uncomm: Aggress., atax., Rare: Stev.-  Indications: As mono-/adjunct.ther. in part.onset seiz. with/without   2400 mg/day have not been studied.
       Johns.syndr., conjunctivit. V.rare: Haematolog.disords., hypersens.  second.generalisat.in adults & childr. over 16 yrs.with epilep., as ad-  Childr.: Admin.only if able to swall.tabs. otherwise. oral susp. In
       syndr. lead. to multiorg.dysfunct.& disseminat.intravasc. coagulat.,   junct.ther.in myoclon. seiz.in adults & adolesc.from 12 yrs.with juven.  mono/adjunct.ther.init.at 8-10 mg/kg/day in 2 div.dos. Therap.eff.
       tox.epiderm.necrolys.,tics., hallucinat., confus., unsteadin., worsen.  myoclon.epilep., prim.gener.tonic-clon.seiz. in adults & adolesc. rom   seen in adjunct.ther.with median maint.dos of approx. 30 mg/kg/day.
       of Parkins. dis., extrapyramid. effs., choreoathetos., seiz.freq. incr.,   16 yrs.with idiopath. gener.epilep.   If clinic.indic.incr.dos.in increm.of max. 10 mg/kg/day at approx.wkly.
       hepat. dysfunct./-fail., lupus-like reacts.  (S3) FILM-COAT. TABS, 46/2.5/0338, 0339  interv.to max. 46 mg/kg/day achiev.desir. respons.
       Warnings and special precautions: Sev. convuls. seiz.incl.status   722150-001: 250 mg, 60, R173,99  Contra-indications: Safety in pregn./childr.bel. 6 yrs. not est., lac-
       epilept.may lead.to rhabdomyolys./ multiorg.dysfunct.& disseminat.   722151-001: 750 mg, 60, R521,98  tat., MAOI not recomm.
       intravasc. coagulat., close monit.of hepat./ren./ haem.abnormal.&   Dosage: Admin.dly.dos.in 2 equal div.dos.  Side-effects: Bld.dyscras., hypersens.reacts., hyponatraem., seiz.,
       clott.paramet.& developm.of unexplain. combin.of rash/fev.& flu-  Monother: Adults & adolesc. 16 yrs & old: Init. recomm.dos:   confus., depress.consciousn. lev., encephalopathy, GI disturbs., CNS
       like sympts., drowsin., worsen.of seiz.contr.dur.1st mnth.of treatm.,   250 mg 2x dly incr.to an init.therap. dos.of 500 mg 2xdly aft.2 wks.   effs., dizzin., headache, nystagm., tremor, vertigo, eye disords. incl.
       incr.incid.of skin rash in childr., incr incid. of rash assoc.with exceed.  May be furth.incr. by 250 mg 2xdly every 2 wks.depend.on respons.   vis.disturbs., arrhythm., AV block, pancreatit., incr.hepat.enzym., hep-
       recomm.dos.& concom. valproate req.immed.withdr., abrupt withdr.   Max.dly dos: 1 500 mg 2xdly.  atit., skin reacts. incl.Stev.-John.syndr., angioed., SLE, alopec., fatig.,
       may provoke rebound seiz., grad.withdr. over 2 wks., monit.for early   Adjunct.ther: Adults (≥ 18 yrs) & adolesc.12-17 yrs.weigh.   asthen., abnorm.bleed.
       signs of hypersens. syndr., monit.weight of child dur.ther.& review   ≥50 kg: Init.therap.dos: 500 mg 2xdly. Dos.may be start.on 1   st  Special precautions: Admin.und.med.supervis., prev.carbamazep.
       dos.if necess., adhere to recomm.dos.esp.if valproate used concom.,   treatm.day. Dly.dos. may be incr.to 1 500 mg 2xdly.depend.on clinic.   hypersens., discont. ther.immed. if hypersens./sev.skin.reacts.S&S oc-
       withdr.immed.in pres.of skin rash unless clearly not drug relat & do   respons. & toler. Dos.chang.may be made in 500 mg 2x dly increm.  cur, concom. alcoh., discont.grad.or und.cover of suit.meds.& close
       not re-instit.ther., report any change in menstr. pattern with introduct.  or decrem.2-4 wkly.  supervis.if abrupt discont.necess., cross. placenta, pass.into breast
       of concom.OC., start./stop. an OC dur ther may req.dos.adjustm., ren.  Adolesc.12-17 yrs.&lt;50 kg: Init.therap.dos: 10 mg/kg 2xdly.start.on   milk, outweigh benef.vs. risk if a woman becom.pregn./start. ther.dur.
                                                                         st
       fail., close monit.in bipolar disord.for poss.suicid. attempts, eval.S/E   1  treatm.day. Maybe incr. up to 30 mg/kg 2xdly depend.on clinic.  pregn. esp.dur. 1  trimest.in which case minim.effect. dos. to be giv.,
                                     st
       bef.driv./operat.machin., lact. intol., excret. in breast milk with ser.  respons.& tol. Dos changes not to exceed incr./decr.of 10 mg/kg 2xdly   monother.advis.in women of child-bear.age, vit.K 1 admin.to mother
       lev.reach.in infts.at which pharmacolog.effs.poss., monother. in childr.   every 2 wks. Use low.effect.dos. Childr.&gt;50 kg: Same as adult dos.  in last wks.of pregn. & to neonat., elderly, no studies in sev. hepat.
       und.12 yrs.not recomm., safety in pregn. & lactat. not est., insuff.info   Contraindications: Pregn., lactat., pyrrolidone derivat. hypersens.   impairm., imp.ren.funct., addit.non-hormon. contracept.in women of
       on use in childr.und. 2 yrs.  Side effects: Infect., nasopharyngit., bld.dyscras., pancreatit., ano-  childbear.potent., low/ decr.white bld.cell/platel.counts, discont.ther.
       Interactions: Anti-epilept.agents which induc. hepat.drug metabol.  rex., incr.mass, psych.disords.incl. hostilit./person.disord., CNS effs.,   if signif. bone-marrow depress.evid., monit.ser.Na lev.bef.init.ther.&
       enzymes signific.enhanc. metabol.halving eliminat.half-life, two   dizzin., headache, atax., convuls., trem., balance disords., diplop., blurr.  reg.aft.in pre-exist.ren. condit.assoc.with low Na lev.& concom.Na-
       fold incr.in oral clear.& reduc.lamotrigine AUC & C max.with hormon.  vis., vertigo, rhinit., incr.cough., sinusit., GI disturbs., skin reacts., alo-  low.meds., concom.meds. metab. by CYP2C19.
       contracept.with breakthrough seiz. report., sod.valproate signific.  pec., myalg., asthen., fatig., accid.inj.  Drug interactions: Incr.CNS eff.with alcoh., reduc. plasma conc.
       reduc.metabol., rifampic. incr.clear., poss.interfer.with folate me-  Warnings and special precautions: Grad. withdr./ tfd.to other   with strong cytochrome P450 enzym.induc.such as phenonbarb./
       tabol.dur.longt.ther.         anti-epilept.ther., excret.in human milk, ren.impairm., monit.ren.  phenytoin, poss.low.conc.of dihydropyridine Ca antagon./anti-epi-
       LAMITOR, Dr Reddy’s Laboratories [P/S]  funct.in sev. imp.hepat.funct.prior to init., elderly, insuff.data avail.  lept. e.g.carbamazepine, reduc. ethinyloestrad./ levonorgestrel AUC
                                                                  values, alt.plasma lev.with viloxazine., poss.enhanc.neurotoxic.with
       Lamotrigine.                  for use in childr.und.12 yrs.  Li, verapamil low.plasma conc., reduc.felodipine AUC values, decr.
       Indications: Adults & childr.over 12 yrs: Monother./add-on   Drug interactions: Decr.inact.metabol.ren.clear. with probenecid.  plasma lev.with cert.meds.metabol.by CYP3A4 & CYP3A5, incr.phe-
       treatm.of part.epilepsy with/ without second.general.ton-clon.seiz.,   LYRICA, Pfizer [P/S] &  nytoin lev.if giv. concom. with dos.high.than 1 200 mg/day.
       & in prim. gen. tonic-clon.seiz. Childr. 2-12 yrs: Add-on treatm. of   Pregabalin
       part.epilep.with/without second gen. tonic-clonic seiz.not satisfact.  Indications: Adult neuropath.pain due to H.Zoster infects.& diabet.  MYSOLINE, Litha [P/S]
       control.with other anti-epilept.meds.  (S5) CAPS. 39/2.5/0264,0266, 0268.  Primidone
       Lennox-Gastaut Syndr: Add-on treatm.of assoc.seiz.  709804-001: 25 mg, 56, R145,13  Indications: Gener.tonic-clonic seiz., part.seiz.with/without sec-
       (S3) TABS, 37/2.5/0051, 0052, 0053, 41/2.5/0375  709805-001: 75 mg, 56, R365,46  ond.generalisat. (tempor.lobe seiz., foc.seiz.), myoclon.jerks & aki-
       704486-001: 25 mg, 60, R109,99  709806-001: 150 mg, 56, R548,20  net.attacks.
       704487-001: 50 mg, 60, R139,20  Dosage: Recomm.start.dos: 75 mg 2xdly. Bas.on indiv. respons.&   (S3) TABS, B/2.5/572
       704488-001: 100 mg, 60, R263,41  tolerabil.dos.may be incr.to 150 mg 2xdly.aft.3-7 day interv. Discont.  745588-018: 250 mg, 100, R372,94
       712217-001: 200 mg , 60, R423,65  grad.over minim.1 wk.    Dosage: Indiv.bas. Grad.withdr.of exist. anticonvuls. & phenobarbi-
       Dosage: Do not exceed max.recomm.dos.esp.in combinat.with   Side effects: CNS effs.most common of which dizzin. & somnol.,   tone over 2 wks.when tfd. pts.& incr dos.to maint.seiz.contr. Given
       valproate. If calcul.dos.,esp.in childr. does not equate to whole tab.  loss of consciousn., confus., ment. impairm., revers.paralys., neutro-  twice dly. Begin with half tab.once.dly.in even. Incr. dly. dos. by half
       admin.dos.as equal to low.no.of whole tabs.  pen., incr. appet., anorex., hypoglycaem., psych./CNS disords., vis.  tab.every 3 days to 2 tabs.dly. Thereaft. incr.dly.dos.every 3 days by 1
       Monotherapy: Adults & childr.over 12 yrs.: Init. 25 mg once dly.  disturbs., diplop., dry eye, eye swell./-pain/-irrit., mydrias., alt.vis.  tab.in adult/ half tab. in childr.und.9 yrs.until contr.obt./ max. dos.tol.
       x2 wks., follow.by 50 mg once dly. x2 wks. Thereaft.dos.may be incr.  depth percept., periph. vis.loss, asthenopia, lacrimat.incr., photop-  giv. As much as 6 tabs/day in adults & 4 tabs/day in childr.
       by max.50-100 mg every 1-2 wks.until optim.respons.achiev. Usual.  sia, oscillopsia, strabism., vertigo, hyperacus., tachycard., 1  degr.  Aveg.dly.maint.dos.: Admin.in 2 equal div.dos. morn.& even.
                                                              st
       maint.dose: 100-200 mg/day admin.once dly or in 2 div.dos. Some   AV block, sinus tachycard., sinus arrythm., sinus bradycard., flush.,   Childr.up to 2 yrs: 1-2 tabs.250-500mg dly. 2-5 yrs: 2-3 tabs.500-
       pts.have reqd. 500 mg/ day.   hypo-/hypertens., periph.coldn., dyspn., nas.dryn., nasopharyngit.,   750 mg dly. 6-9 yrs: 3-4 tabs. 750-1000 mg dly. Adults & childr.over
       Add-on therapy: Adults & childr.over 12 yrs.: Pts.not tak.sod.  cough, nas.congest., epistax., rhinit., snor., throat tightn., GI disturbs.,   9 yrs: 3-6 tabs.750-1500 mg dly.
       valproate: Init: 50 mg once dly x2 wks.follow.by 100 mg/day in 2   sweat., rash, musc.twitch./- cramp/-stiffn., joint swell., myalg,. ar-  Contraindications: Ac.intermitt.porphyr. concom. phenobarbit.
       div.dos.x2 wks. thereaft.dos.may be incr.by max. 100 mg every 1-2   thralg., neck/back/limb pain, rhabdomyolys., cervic.spasm., dysur.,   (except when tfd.), sev.imp. hepat./ ren./ resp.funct., pregn.& lactat.
       wks.until optim.respons.achiev. Usual.maint.dos. to achieve optim.  urin.incontin. / retent., oligur., ren.fail., erect.dysfunct., delay. ejacu-  Side-effects: CNS effs., listlessn., atax., vis. disturbs., nystagm., GI
       respons: 200-400 mg/day in 2 div. dos.   lat., sex.dysfunct., amenorrh., dysmenorrh., breast pain/-discharge,   disturbs., skin. reacts.incl. maculopapul./morbilliform/scarlatiniform.
       Pts.tak.sod.valproate: Init: 25 mg every altern. day x2 wks., follow   hypertrophy breast, fatig., oed./periph.oed., abnorm.gait, asthen.,   rashes, exfol. dermatit., Stev.-Johnson syndr., tox. epiderm.necrolys.,
       by 25 mg once dly.x2 wks. thereaft.dos.may be incr.by max.25-50 mg/  fall, thirst, tight chest, exacerbat.pain, pyrex., rigors, anasarca, incr.  lupus erythematos., personal. chang.incl.psychot.reacts., megablast.
       day every 1-2 wks.until optim.respons.achiev. Usual maint.dos.to   weight., withdr.sympts., CHF/ deteriorat.HF, resp.fail.& coma with   anaem.& other bld.dyscras., hepato-bil.disords., arthralg., osteoma-
       achieve optim.respons: 100-200 mg/ day giv.once a day/in 2 div.dos.  concom. CNS depress., hypersens.reacts.incl.angioed.& urticar.,   lac., dupuytrens contracture, polyur., sex. funct.impairm., headache,
       Childr. 2-12 yrs: Pts.not tak.sod.valproate: Init.0,6 mg/kg bm/  swollen tong., face swell., prurit.  dizzin., oed.of legs, thirst, poss.hepat.damage, congenit.abnorm.in
       day in 2 div.dos.x2 wks., follow. by 1,2 mg/kg/day x2 wks. There-  Warnings and special precautions: Reproduct. toxic.in anim., do   infts. of epilept. mothers, decr.folate lev.with prolong. use, coagu-
       aft.the dos.should be incr.by a max. 1,2 mg/kg every 1-2 wks.until   not use in pregn., not recomm.in breast feed., pres.in milk.of rats, imp.  lat.disords.in neonates.
       optim. respons.achiev. Usual maint.dos.to achieve optim.respons:   ren.funct., pts.receiv.haemodialys., incr.accid.injur.partic.in elderly,   Special precautions: Poss.breakthrough bleed.& fail.OC ther.,
       5-15 mg/kg/day in 2 div.dos. Max. dly. dos.of 400 mg not to be exceed.  pts.to familarise themselv.with potent.S/E, CHF, discont.if sympts.of   withdr.eff.in neonates of treat. mothers, admin.vit.K 1 through last
       Pts.tak.sod.valproate: Init: 0,15 mg/kg bm/day once dly x 2wks.   angioed.occ., potent. resp.fail.with concom.antidepress., lact intol.,   mnth.of pregn.to prev. coag.disords.in neonates, in absence of pre-
       follow.by 0,3 mg/kg/day once a day x2 wks. Thereaft.incr.dos by   safety & effectiven.in pts.bel.18 yrs.not est.  treatm. admin.10 mg vit K 1 to mother at time of deliv. & 1 mg to neo-
       max. 0,3 mg/kg every 1-2 wks.until optim.respons.achiev. Usual   Drug interactions: Addit.to cognit.& gross mot. funct.impairm.from   nate.immed., if attacks more freq. at specif.time (eg nocturn./event
       maint. dos: 1-5 mg/kg/day once dly.or in 2 div.dos. Max.dly.dos.of   oxycodone, effs.of ethanol & lorazepam.potent., resp.fail.& coma with   assoc.) consid. adjust.dos.at the appropr.time, Vit.D suppl. poss. dur.
       200 mg not to be exceed. Pts.aged 2-6 yrs. may require maint. dos.   concom. CNS depress.  long term ther., consid.folic.acid.& vit B 12 supplem. in pts.at risk dur.
       at higher end of scale.       See also MDR page 625.       pregn., if megaloblast. anaem develops discont.ther., childr., elderly,</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page67.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page63.html">63</a>&nbsp;&nbsp;&nbsp;<a href="page64.html">64</a>&nbsp;&nbsp;&nbsp;<a href="page65.html">65</a>&nbsp;&nbsp;&nbsp;<a href="page66.html">66</a>&nbsp;&nbsp;&nbsp;<a href="page67.html">67</a>&nbsp;&nbsp;&nbsp;<a href="page68.html">68</a>&nbsp;&nbsp;&nbsp;<a href="page69.html">69</a>&nbsp;&nbsp;&nbsp;<a href="page70.html">70</a>&nbsp;&nbsp;&nbsp;<a href="page71.html">71</a>&nbsp;&nbsp;&nbsp;<a href="page72.html">72</a>&nbsp;&nbsp;&nbsp;<a href="page73.html">73</a>
             </td>
             <td width="35%"><a href="page69.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page69.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
